Wenli Diao

864 total citations
29 papers, 655 citations indexed

About

Wenli Diao is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Wenli Diao has authored 29 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Wenli Diao's work include MicroRNA in disease regulation (6 papers), RNA modifications and cancer (5 papers) and Epigenetics and DNA Methylation (4 papers). Wenli Diao is often cited by papers focused on MicroRNA in disease regulation (6 papers), RNA modifications and cancer (5 papers) and Epigenetics and DNA Methylation (4 papers). Wenli Diao collaborates with scholars based in China, United States and Czechia. Wenli Diao's co-authors include Ke Zen, Chen‐Yu Zhang, Limin Li, Hongqian Guo, Jing Zhang, Wei Yao, Dong Wang, Wenmin Cao, Xiaozhi Zhao and Meng Ding and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Wenli Diao

27 papers receiving 649 citations

Peers

Wenli Diao
Qifeng He China
Sze Keong Tey Hong Kong
Jie Shi China
Shikha Saini United States
Qifeng He China
Wenli Diao
Citations per year, relative to Wenli Diao Wenli Diao (= 1×) peers Qifeng He

Countries citing papers authored by Wenli Diao

Since Specialization
Citations

This map shows the geographic impact of Wenli Diao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenli Diao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenli Diao more than expected).

Fields of papers citing papers by Wenli Diao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenli Diao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenli Diao. The network helps show where Wenli Diao may publish in the future.

Co-authorship network of co-authors of Wenli Diao

This figure shows the co-authorship network connecting the top 25 collaborators of Wenli Diao. A scholar is included among the top collaborators of Wenli Diao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenli Diao. Wenli Diao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Xiaohong, Wenli Diao, Wenmin Cao, et al.. (2025). The N6‐methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression. FEBS Journal. 292(13). 3477–3493.
2.
Zhang, Baochao, Wei Chen, Wenli Diao, et al.. (2025). SFXN1 promotes bladder cancer metastasis by restraining PINK1-dependent mitophagy. Oncogene. 44(32). 2893–2906. 1 indexed citations
3.
Yang, Yang, Wei Chen, Hongwei Shen, et al.. (2024). GALNT12 suppresses the bone-specific prostate cancer metastasis by activating BMP pathway via the O-glycosylation of BMPR1A. International Journal of Biological Sciences. 20(4). 1297–1313. 4 indexed citations
4.
Liu, Shujun, Minghao Zheng, Wenli Diao, et al.. (2024). Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer. Molecular Cancer. 23(1). 30–30. 19 indexed citations
5.
Du, Lin, Baojun Wang, Weixu Chen, et al.. (2023). LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p/SOX4 axis and activating IFNγ-JAK2-STAT1 pathway. Cancer Letters. 578. 216463–216463. 6 indexed citations
6.
Liu, Shujie, Xiaozhi Zhao, Yuhang Li, et al.. (2023). ROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy (Adv. Healthcare Mater. 21/2023). Advanced Healthcare Materials. 12(21). 1 indexed citations
7.
Gao, Jie, Baojun Wang, Hongwei Shen, et al.. (2023). MIOX inhibits autophagy to regulate the ROS -driven inhibition of STAT3/c-Myc-mediated epithelial-mesenchymal transition in clear cell renal cell carcinoma. Redox Biology. 68. 102956–102956. 15 indexed citations
8.
Wang, Guoli, Xin He, Wenmin Cao, et al.. (2023). WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2. Oncogenesis. 12(1). 47–47. 3 indexed citations
9.
Jiang, Bo, Xiaozhi Zhao, Wei Chen, et al.. (2022). Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation. Nature Communications. 13(1). 4141–4141. 27 indexed citations
10.
Ding, Meng, Xiaozhi Zhao, Wenli Diao, et al.. (2022). Cancer-associated fibroblasts promote the stemness and progression of renal cell carcinoma via exosomal miR-181d-5p. Cell Death Discovery. 8(1). 439–439. 25 indexed citations
11.
Zhang, Qing, Wenlong Zhang, Tingsheng Lin, et al.. (2022). Mass cytometry reveals immune atlas of urothelial carcinoma. BMC Cancer. 22(1). 677–677. 8 indexed citations
12.
Zhang, Wenlong, Xin He, Wenmin Cao, et al.. (2022). Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis. Journal of Hematology & Oncology. 15(1). 93–93. 29 indexed citations
13.
Lu, Qun, Wei Chen, Wenli Diao, et al.. (2022). circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5. Cell Death Discovery. 8(1). 243–243. 17 indexed citations
14.
Qin, Haixiang, Lin Du, Bo Jiang, et al.. (2022). Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers. Cancer Cell International. 22(1). 101–101. 15 indexed citations
15.
Qin, Haixiang, Yang Yang, Bo Jiang, et al.. (2021). SOX9 in prostate cancer is upregulated by cancer‐associated fibroblasts to promote tumor progression through HGF/c‐Met‐FRA1 signaling. FEBS Journal. 288(18). 5406–5429. 20 indexed citations
16.
Jiang, Bo, Wei Chen, Haixiang Qin, et al.. (2019). TOX3 inhibits cancer cell migration and invasion via transcriptional regulation of SNAI1 and SNAI2 in clear cell renal cell carcinoma. Cancer Letters. 449. 76–86. 19 indexed citations
17.
Diao, Wenli, Wei Chen, Wenmin Cao, et al.. (2019). Astaxanthin protects against renal fibrosis through inhibiting myofibroblast activation and promoting CD8+ T cell recruitment. Biochimica et Biophysica Acta (BBA) - General Subjects. 1863(9). 1360–1370. 26 indexed citations
18.
Yuan, Hui, et al.. (2019). Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence. BMC Urology. 19(1). 90–90. 15 indexed citations
19.
Li, Limin, Tao Zhang, Wenli Diao, et al.. (2015). Role of Myeloid-Derived Suppressor Cells in Glucocorticoid-Mediated Amelioration of FSGS. Journal of the American Society of Nephrology. 26(9). 2183–2197. 29 indexed citations
20.
Diao, Wenli, Fangfang Jin, Bing Wang, et al.. (2014). The protective role of myeloid-derived suppressor cells in concanavalin A-induced hepatic injury. Protein & Cell. 5(9). 714–724. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026